Physician profile
Vickram Singh Reehal
NPI 1235347188
$28,970.16
in general payments reported to CMS, 2019-2025
9 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $12K · 2021: $6,165 · 2022: $5,546 · 2023: $4,395 · 2024: $134 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,275 · Food and Beverage: $306 · Education: $73.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,275.00 |
| Food and Beverage | $306.29 |
| Education | $73.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28,113.47 | 2019-2024 | Taltz, Zepbound |
| Abbvie INC. | $380.37 | 2019-2024 | |
| Genzyme Corporation | $124.99 | 2025 | |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Pfizer INC. | $73.20 | 2024 | |
| Glaxosmithkline, LLC. | $67.06 | 2019-2022 | |
| Genentech USA, INC. | $49.95 | 2021 | |
| Novo Nordisk INC | $38.86 | 2020 | |
| Amgen INC. | $22.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vickram Reehal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.